Gilead Sciences Inc has decided to discontinue the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) due to futility based on a planned analysis. The study evaluated the combination of magrolimab plus azacitidine as first-line treatments for higher-risk MDS. The FDA had previously placed a partial clinical hold on the study due to suspected unexpected serious adverse reactions, but lifted the hold in April. Gilead is working on next steps for patients enrolled in the study.